Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBT (2023 - 2025)

Historic EBT for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$31.8 million.

  • Tonix Pharmaceuticals Holding's EBT fell 10102.29% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.7 million, marking a year-over-year increase of 3109.61%. This contributed to the annual value of -$136.7 million for FY2024, which is 3920.11% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's EBT stood at -$31.8 million, which was down 10102.29% from -$27.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's EBT ranged from a high of -$15.8 million in Q3 2024 and a low of -$77.3 million during Q2 2024
  • Moreover, its 3-year median value for EBT was -$27.3 million (2023), whereas its average is -$29.7 million.
  • Over the last 5 years, Tonix Pharmaceuticals Holding's EBT had its largest YoY gain of 6462.14% in 2025, and its largest YoY loss of 10102.29% in 2025.
  • Tonix Pharmaceuticals Holding's EBT (Quarter) stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then crashed by 41.62% to -$31.8 million in 2025.
  • Its EBT was -$31.8 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$16.1 million in Q1 2025.